Skip to main content

Table 3 Adverse events through week 52 and week 112 for patients who received at least one administration of golimumab

From: Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age

  Patients
< 65 years
Patients ≥ 65 years Patients < 70 years Patients ≥ 70 years Patients < 75 years Patients ≥ 75 years
Patients, n 508 76 547 37 574 10
Through week 52
 Mean duration of follow-up, weeks 43.5 43.2 43.6 41.8 43.5 40.5
 Mean number of golimumab infusions 5.9 5.8 5.9 5.6 5.9 5.4
 Patients with ≥ 1 AE 355 (69.9) 52 (68.4) 379 (69.3) 28 (75.7) 397 (69.2) 10 (100.0)
 Patients with infections 214 (42.1) 30 (39.5) 227 (41.5) 17 (45.9) 239 (41.6) 5 (50.0)
 Patients with ≥ 1 SAE 45 (8.9) 9 (11.8) 49 (9.0) 5 (13.5) 50 (8.7) 4 (40.0)
 Patients with serious infections 7 (1.4) 4 (5.3) 10 (1.8) 1 (2.7) 10 (1.7) 1 (10.0)
Through week 112
 Mean duration of follow-up, weeks 96.6 90.9 96.4 88.7 96.2 76.9
 Mean number of golimumab infusions 12.0 11.3 12.0 10.9 12.0 9.4
 Patients with ≥ 1 AE 417 (82.1) 61 (80.3) 445 (81.4) 33 (89.2) 468 (81.5) 10 (100.0)
 Patients with infections 262 (51.6) 42 (55.3) 279 (51.0) 25 (67.6) 297 (51.7) 7 (70.0)
 Patients with ≥ 1 SAE 90 (17.7) 19 (25.0) 97 (17.7) 12 (32.4) 102 (17.8) 7 (70.0)
 Patients with serious infections 27 (5.3) 9 (11.8) 32 (5.9) 4 (10.8) 34 (5.9) 2 (20.0)
  1. Data presented as n (%) unless otherwise noted
  2. AE adverse event, SAE serious adverse event